. 2020 Sep 14;26(6):575–583. doi: 10.5152/dir.2020.19615

Table 4.

Meta-analysis of efficacy in combined group and control group

Outcomes	BCLC stage	No of studies	RR (95% CI)	Z	P	I² (%)	P_hetero
CR	Overall data	17	2.56 (2.09, 3.14)	9.03	0.000	16.6	0.259
	BCLC A	2	1.86 (0.96, 3.61)	1.83	0.068	0.0	0.744
	BCLC B	10	2.07 (1.59, 2.69)	5.42	0.000	0.0	0.623

PR	Overall data	17	1.31 (1.13, 1.52)	3.5	0.000	51.8	0.007
	BCLC A	2	1.27 (0.90, 1.80)	1.37	0.170	51.9	0.149
	BCLC B	10	1.57 (1.27, 1.94)	423	0.000	29.2	0.176

SD	Overall data	16	0.60 (0.47, 0.76)	4.21	0.000	21.8	0.211
	BCLC A	1	0.66 (0.28, 1.55)	0.95	0.341	^*
	BCLC B	10	056 (0.41, 0.76)	3.72	0.000	47.6	0.046

PD	Overall data	16	0.48 (0.38, 0.59)	6.78	0.000	28	0.148
	BCLC A	1	0.32 (0.03, 2.89)	1.02	0.307
	BCLC B	10	0.51 (0.40, 0.66)	5.08	0.000	46.4	0.058

ORR	Overall data	17	1.69 (1.54,1.85)	11.33	0.000	13.4	0.296
	BCLC A	2	1.40 (1.11, 1.78)	2.82	0.005	29.1	0.235
	BCLC B	10	1.79 (1.58, 2.20)	9.29	0.000	15.4	0.301

1-year OS	Overall data	17	1.36 (1.28,1.44)	9.87	0.000	0.0	0.622
	BCLC A	3	1.50 (1.12, 2.00)	2.74	0.006	0.0	0.762
	BCLC B	8	1.40 (1.29, 1.53)	7.69	0.000	0.0	0.622

2-year OS	Overall data	15	1.56 (1.40,1.74)	7.81	0.000	0.0	0.981
	BCLC A	2	1.92 (1.17, 3.18)	2.56	0.011	0.0	0.483
	BCLC B	7	1.60 (1.36, 1.88)	5.76	0.000	0.0	0.779

3-year OS	Overall data	8	2.07 (1.67,2.57)	6.63	0.000	0.0	0.728
	BCLC A	1	1.67 (0.45, 6.21)	0.76	0.000
	BCLC B	4	2.02 (1.53, 2.66)	4.96	0.446	0.0	0.501

BCLC, Barcelona Clinic Liver Cancer stage; RR, risk ratio; 95% CI, 95% confidence interval; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; ORR, objective response rate; OS, overall survival

Due to the nature of statistical analysis, the value was absent.